Table 5.
Mixed models relating changes in the sex hormones/SHBG and CIMT progression, stratified by treatment group
| On-trial changes in hormones | Placebo (n = 85)a
|
Estradiol (n = 91)
|
||
|---|---|---|---|---|
| CIMT progression rate/yr (se)b | P value | CIMT progression rate/yr (se)b | P value | |
| Estrone (pg/ml) | −0.03 (0.08) | 0.75 | −0.10 (0.06) | 0.19 |
| Total E2 (pg/ml) | −0.70 (0.46) | 0.13 | −0.09 (0.07) | 0.18 |
| Free E2 (pg/ml) | −22.9 (15.8) | 0.15 | −3.29 (2.9) | 0.26 |
| Total T (ng/dl) | −1.23 (0.64) | 0.05 | −0.29 (0.28) | 0.30 |
| Free T (pg/ml) | −4.58 (2.7) | 0.09 | 0.61 (1.2) | 0.61 |
| Androstenedione (pg/ml) | 0.003 (0.01) | 0.83 | −0.02 (0.01) | 0.12 |
| DHEA (ng/ml) | 1.23 (2.38) | 0.60 | −1.1 (1.65) | 0.51 |
| SHBG (nmol/liter) | −0.12 (0.26) | 0.65 | −0.20 (0.10) | 0.046 |
Each model adjusted for age and BMI. E2, Estradiol; T, testosterone.
a
Placebo women (n = 4) who took exogenous estrogens during the trial were excluded.
b
CIMT progression rate (micrometers per year) per unit change in the sex hormone levels.